Trials in Indiana.
59 APOE4-relevant Alzheimer’s trials run in Indiana — 27 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- Family genetics study, not APOE4-specificNCT00064870Alzheimer's Disease Genetics Study
This study collects blood or tissue samples from families with several members who have Alzheimer's or another dementia. Researchers want to find genes that…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- Drug trial, genotype not specified in sourceNCT00667810Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
- Rare inherited mutation families, not APOE4NCT00869817Dominantly Inherited Alzheimer Network (DIAN)
This is an observational study, meaning no drug or treatment is given. Researchers follow families with a rare inherited gene mutation that causes Alzheimer's,…
- Cancer trial, not for healthy carriersNCT01227954Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
This trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…
- Huntington's study, not about APOE4NCT01574053Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…
- Not for APOE4 carriers; mutation carriers onlyNCT01760005Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
This trial tests several investigational drugs, including gantenerumab, solanezumab, E2814 and lecanemab, against placebo. It asks whether they slow cognitive…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Diagnostic test study, not APOE4-specificNCT03560960Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
This study is testing whether a single injection of pramlintide, a diabetes drug already approved by the FDA, can power a blood test for early Alzheimer's.…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- General prevention, genotype not consideredNCT04270474Reducing Risk of Dementia Through Deprescribing
This trial is testing whether helping older adults stop or reduce certain common medications called anticholinergics — used for things like bladder control,…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
- Drug trial, genotype not specified, ARIA riskNCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…
- Open to carriers, not 4-specificNCT05231785A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
This trial is testing ALN-APP, a drug injected directly into the spinal fluid that is designed to reduce production of amyloid precursor protein in the brain.…
- Not for APOE4 alone; mutation carriers onlyNCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
This trial tests two investigational drugs, E2814 and lecanemab, in people who carry a gene mutation that causes early-onset Alzheimer's. It measures changes…
- Early drug trial, not 4-specificNCT05462106A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
This trial tests ACI-24.060, an active vaccine-style treatment meant to prompt the body to make its own antibodies against amyloid, a sticky protein linked to…
- Diagnosis study, genotype not consideredNCT055152245-Cog 2.0: A Pragmatic Clinical Trial
This trial tests whether a quick memory and thinking check, called the 5-Cog, helps primary care doctors spot mild cognitive impairment and dementia more often…
- Open to carriers, not 4-specificNCT05531656A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
This trial is testing CT1812, an experimental drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia confirmed by…
- Familial mutation only, not APOE4NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2)…
- Lifestyle study, but for diagnosed patientsNCT05573490Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
This study tests whether computer-based brain training plus Tai Chi and Qi Gong can help people with early-onset Alzheimer's keep up their thinking, daily…
- Open to carriers, genotype not consideredNCT05601817Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure
This trial is testing three behavioral interventions for older adults who have both heart failure and mild cognitive impairment: a virtual reality cognitive…
- Open to carriers, not 4-specificNCT05643144Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes
This trial is testing a digital tool called CGM ASSIST, which pairs a wearable blood sugar monitor with easy-to-read interactive displays. The goal is to help…
- Caregiver study, genotype not relevantNCT05733520I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
This trial is testing a mobile app called Brain CareNotes to see whether it reduces stress and burden in unpaid caregivers of people with Alzheimer's or…
- Device study, for diagnosed residents, not 4-specificNCT06045988Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease
This study tests a sensor that tracks sleep without anything worn on the body. It is used with people who have Alzheimer's or related dementia and live in…
- Caregiver app study, genotype not involvedNCT06099197I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms in Hispanic Individuals
This study tests a smartphone app called Brain CareNotes, designed to help unpaid Hispanic family caregivers manage difficult behavior and mood symptoms in a…
- Not for APOE4 carriers; inherited mutations onlyNCT06384573DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This trial gives lecanemab, an anti-amyloid antibody, to people who carry a gene mutation that causes inherited Alzheimer's, and who already took part in an…
- Open to carriers, not 4-specificNCT06403345A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
This study tests a structured program of outdoor nature activities — things like dog walking, gardening, hiking, and outdoor yoga — for people already…
- Diagnosed patients only, not APOE4-specificNCT06582706Nicotinic Acid for the Treatment of Alzheimer's Disease
This small study gives people with mild-to-moderate Alzheimer's a single 500 mg dose of extended-release niacin (vitamin B3), or a placebo. Researchers measure…
- Not for APOE4; rare inherited mutations onlyNCT06647498A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This trial tests remternetug, an anti-amyloid antibody drug, in people who carry a gene mutation that causes early-onset Alzheimer's and who still have normal…
- Drug trial, APOE4 handling not statedNCT06653153A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…
- Drug trial, genotype not specifiedNCT06709014A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
This trial tests whether buntanetap, a daily pill, slows memory and thinking decline and helps everyday function in adults 55 to 85 with early Alzheimer's. It…
- Open to carriers, not 4-specificNCT06976203A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
MINDSET 2 is testing KarXT plus KarX-EC — a combination drug regimen that works on muscarinic receptors in the brain — to see whether it improves cognition in…
- Caregiver trial, genotype irrelevantNCT07054385I-CARE Rural Pilot: Intervention for Rural-Dwelling Dementia Caregivers
This trial is testing a smartphone app called Brain CareNotes designed to help people who care for a loved one with Alzheimer's or a related dementia.…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.